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Abstract. Background/Aim: The combination of plasma
tissue inhibitor of metalloproteinases-1 (1) and CEA has
been shown to have utility in early detection of colorectal
cancer (2). A prospective study was performed to validate
previous findings. Patients and Methods: Individuals
undergoing large bowel endoscopy were prospectively
included (N=1965). Baseline data and co-morbidity were
recorded. The primary end-point was the detection of CRC.
Plasma was obtained before endoscopy and TIMP-1 and
CEA levels were determined using an automated analysis
platform when all samples were collected. Results: CRC
was detected in 32 individuals, 24 with colonic cancer (CC)
and 8 with rectal cancer (RC). Other findings were 265
with adenomas and 889 with non-neoplastic pathology. The
biomarker levels were elevated in plasma from patients with
CRC, but also from patients with various co-morbidities
compared to individuals without any findings at endoscopy.
Univariate analysis demonstrated that both markers were
significant predictors of CRC. The odds ratios (OR) for an
elevated TIMP-1 level for the detection of CRC was 6.2
[95% confidence interval (CI)=3.1-13.0, p<0.0001] and for
an elevated CEA level was 2.4 (95% CI=1.9-2.9,
p<0.0001). A subset analysis with CC as the end-point
showed an OR for TIMP-1 of 7.0 (95% CI=3.2-15.3,
p<0.0001). Multivariable analysis including TIMP-1, CEA
and age resulted in an OR for TIMP-1 of 2.0 (95% CI=0.7-
5.2, p=0.078) and for CEA the OR was 2.2 (95% CI=1.8-
2.8, p<0.0001). Conclusion: This prospective study
validates a previous study testing the detection of CRC
based on TIMP-1 and CEA levels (3).
Population screening for CRC using faecal occult blood test
(FOBT) results in more individuals being diagnosed with
an early-stage disease (4, 5), which translates into improved
survival compared to CRC cases not detected by screening
(6, 7). However, due to a relatively low compliance with
and thereby a low clinical sensitivity of FOBT screening
(8-10), improved methods for screening and early detection
of CRC are required (11-13). 
Carcinoembryonic antigen (CEA) in serum was the first
soluble biomarker for use in CRC and is still the only
soluble biomarker recommended for used for monitoring
purposes in CRC (14). However, the level of CEA is
strongly dependent on the stage of disease, with a low
positive rate being found in early-stage disease, and
therefore the sensitivity of CEA in screening rays between
8% and 89% at specificities of 70% to 95% (15). The latest
ASCO guidelines, accordingly, state that CEA is not
recommended for use as a screening test for CRC (15).
Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1)
has been suggested for the early detection of CRC (1), as
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high plasma TIMP-1 levels were shown to identify patients
with colonic cancer (CC) with a sensitivity of 63% at 98%
specificity, patients with early CC (stage I and II) with a
sensitivity of 56% at 98% specificity, and patients with right-
sided CC with a sensitivity of 72% at 98% specificity (1). A
subsequent study by independent investigators confirmed that
the level of plasma TIMP-1 protein may be an important
marker in early detection of CRC, showing 42% sensitivity
at 95% specificity (16). Of specific interest was that by
combining TIMP-1 with CEA measurements, the
discrimination was significantly improved (1). Most previous
studies used retrospectively collected plasma samples from
patients with known CRC and healthy blood donors as
control individuals. This approach may introduce bias since
blood donors may not be representative of a CRC-related
background population. Another potential confounder in such
studies is that samples from patient cohorts and healthy
volunteers may not be collected simultaneously and therefore
not according to similar standard operating procedures. 
The Tumor Marker Utility Grading System (TMUGS)
guidelines (17) suggest that retrospectively obtained results
must be prospectively validated in order for a biomarker to
reach clinical acceptance and subsequent implementation.
Such prospective studies should take all possible pre-, per-
and postanalytical aspects into consideration, including the
use of strict and identical sampling, handling and storage
procedures for specimens from all recruited individuals
(18). Furthermore, external validation is necessary for the
final evaluation of a test for screening of CRC. 
The present prospective study was designed to evaluate
the utility of CEA and TIMP-1 as screening markers for
CRC in order to validate our earlier prospective study (3).
The present study was based on an independent population
consisting of both symptomatic and non-symptomatic
individuals from another continent (Australia) and therefore
with a different distribution of baseline characteristics.
The design of the entire protocol and subsequent study
was similar to the previous study, including blood
collection, handling and storage (19). The St. George
Hospital and Community Health Service Kogarah, NSW,
Australia, approved the protocol (no. 04/122) including the
Case Record Form), and the study was performed according
to the Helsinki II declaration. In the informed consent,
requests to analyse other relevant already established or
new biomarkers pending ad hoc permission from the Ethics
Committee were included and approved with the signature
of the recruited individuals. We followed the REMARK
guidelines whenever applicable for reporting the study (20).
Baseline data were collected on each recruited individual
and included data on co-morbidity, medication and
lifestyle. The latter two were self-reported. All findings and
co-morbidities were registered using ICD-10 codes
(HTTP://WWW.WHO.INT/CLASSIFICATIONS/ICL/EN/).
Plasma levels of TIMP-1 and CEA were determined
using the Abbott ARCHITECT® i2000 automated
immunoassay system utilizing a two-step dual monoclonal
immunoassay. The ARCHITECT® i2000 is a high-
throughput immunoassay analyser that utilizes
paramagnetic microparticle capture and chemiluminescent
detection technology. Assays were run at the Abbott Centrer
of Excellence Research Laboratories in Munich, Germany.
Abbott in-house research prototype TIMP-1 reagents (21),
and on-market ARCHITECT CEA reagents were used for
these analyses.
Patients and Methods
Statistics. The database was managed and calculations performed
using the SAS system (SAS v9.2; SAS Institute, Cary, NC, USA).
Descriptive statistics are presented by the median, minimum and
maximum for continuous variables. Tests for location were
performed using the Mann–Whitney test and the proportion of all
possible pairs with the first biomarker level exceeding the other
are presented. The estimation of differences between levels of the
two biomarkers for individuals with co-morbidity or not, and
lifestyle variables was performed using a linear model with the
biomarkers log-transformed and adjusted for gender and age. The
probability of CRC was estimated using logistic regression
analysis modelling the probability for CRC. Goodness of fit was
assessed using the Hosmer–Lemeshow test. Biomarkers were
initially considered as continuous variables on the log scale and
assessment of linearity was carried out. Continuous biomarker
levels were scored using the log-transformed values (log base 2).
The odds ratios (ORs) of CRC versus not having CRC are
presented with 95% confidence intervals (CIs). Receiver operating
characteristic curves (ROC) were estimated and the areas under
the ROC curve (AUC) were calculated. Multivariable analyses
were carried out on the entire set, as well as subsets, using logistic
regression analysis. Age is categorized and entered as a class
variable. The multivariable analyses also include covariates:
gender, co-morbidity and lifestyle variables. Model selection was
made including tests for possible interactions and the final
multivariable model only included covariates which were
significant. p-Values less than 5% were considered significant.
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Table I. Patients’ characteristics.
Finding N Male, (%) Median age, Comorbidity, 
years n (%)
Colon cancer 24* 75.0 65 17 (70.8)
Rectal cancer 8 75.0 71 4 (50.0)
Adenoma 271 60.2 65 224 (82.7)
Non-malignant 898 47.4 65 700 (78.0)
No finding 789 45.8 56 553 (70.1)
*Carcinoembryonic antigen (CEA) and Tissue inhibitor of
metalloproteinases-1 (TIMP-1) levels were available for 23.
Results
Two thousand and five individuals were included in the
study and data for 1990 were evaluable. The median age
was 59 years (20-104 years). The study included 1,016
males and 974 females. One thousand eight hundred and
ninety were of European ethnicity and 98 were not (two
had missing data regarding ethnicity).
The results of the endoscopy examination are shown in
Table I, classified as colorectal cancer, adenoma, non-
malignant findings and no findings, and include
demographic data as well as co-morbidity (at least one co-
morbidity registered). The TNM stages of the 32 patients
with CRC detected were T1: 2, T2: 2, T3: 17, T4: 6, Tx: 1
and 4 were classified as in situ. For nodal status, 13 were
N0, 11 N1 and 6 N2 (2 were Nx). Seven patients had M1
disease, 12 M0 and 13 Mx.
Complete blood collection sets were available for 1,965
individuals and EDTA plasma was used for biomarker
analyses. Plasma TIMP-1 was a median level of 85.9 ng/ml
(range 26.3-343.9 ng/ml , lower quartile 75.6, upper
quartile 100.8 ng/ml) and plasma CEA had median level of
1.1 ng/ml (range 0-933.5, lower quartile 0.6, upper quartile
1.9 ng/ml). The rank correlation (Spearman) between the
two biomarkers was 0.20 (p<0.0001). Similarly the
correlations between TIMP-1, CEA and age were 0.49
(p<0.0001) and 0.25 (p<0.0001) respectively – both
biomarker levels increase with age.
The distributions of TIMP-1 and CEA stratified by the
results of the endoscopic examination are shown in Table
II. There were 32 patients detected as having CRC,
however one did not have CEA or TIMP-1 levels available.
The presence of co-morbidity was associated with the
levels of the two biomarkers. Analysis of the levels of the
biomarkers and the selected co-morbidities using a linear
model and adjusted for age and gender are shown in Table
III. The Table shows the relative difference between those
with the denoted co-morbidity and those individuals not
having any co-morbidity and include the 95% CI for the
difference. Plasma TIMP-1 was significantly elevated in
those with cardiovascular disease, chronic lung disease and
diabetes, whereas CEA was only significantly elevated for
those with cardiovascular disease. 
The primary purpose of the study was to assess the
discrimination between those with CRC and the remaining
study subjects based on the biomarker levels. Univariate
analyses between the results of the endoscopic examination
and TIMP-1 and CEA are shown in Table IV. The Table
gives the AUC under the ROC curve as a measure of
discrimination for each pairwise comparison for TIMP-1
(upper) and CEA (lower). It can be seen that both TIMP-1
and CEA are significantly elevated for those with CC. 
A univariate analysis of patients with CRC versus the
remaining individuals using a logistic regression analysis
demonstrated that TIMP-1, as well as CEA, were associated
with the diagnosis of CRC: TIMP-1: OR=6.2, 95% CI=3.1-
13.0, p<0.0001 (AUC=0.695); CEA: OR=2.4, 95% CI=1.9-
2.9, p<0.0001 (AUC=0.731). A multivariate analysis
including TIMP-1, CEA and age was then performed and
resulted in only CEA being significantly indicative of CRC.
The OR for TIMP-1 was 2.0 (95% CI=0.7-5.2) and CEA
was 2.2 (95% CI=1.8-2.8). The AUC of this model was
0.753. The ROC curves for each of these analyses are
shown in Figure 1.
A secondary univariate analysis evaluated the
relationships between the two biomarkers and CC only. The
results showed that TIMP-1 and CEA were significantly
associated with CC [TIMP-1: OR=7.0, 95% CI=3.2-15.3,
Christensen et al: TIMP-1 and CEA for Detection of CRC
4937
Table II. Distribution of TIMP1* and CEA*.
Biomarker N Median Minimum Maximum Lower quartile Upper quartile
Adenoma TIMP1 265 91.5 38.5 297.7 81.8 104.4
CEA 265 1.3 0.0 55.8 0.7 2.1
Colonic cancer TIMP1 23 108.1 71.1 343.9 95.7 138.7
CEA 23 2.7 0.2 933.5 0.8 51.4
Non-malignant findings TIMP1 889 85.9 47.7 325.3 75.2 101.3
CEA 889 1.1 0.0 40.2 0.6 1.9
No findings TIMP1 780 83.9 26.3 337.3 74.9 97.4
CEA 780 1.1 0.0 36.2 0.6 1.8
Rectal cancer TIMP1 8 98.1 61.4 297.3 71.2 142.6
CEA 8 8.7 1.6 231.7 2.0 76.2
*Levels of TIMP-1 and CEA are in ng/ml.
p<0.0001 (AUC=0.742); CEA: OR=2.3, 95% CI-1.80-2.8,
p<0.0001 (AUC=0.667)]. A multivariable analysis was
carried-out including only CEA, TIMP-1 and age due to the
small number of CRC cases detected. The multivariable
analysis showed that both biomarkers were significantly
associated with the diagnosis of CRC (TIMP-1: OR=2.9,
95% CI=1.0-7.8, p=0.041; CEA: OR=2.1, 95% CI=1.6-2.7,
p<0.0001).
Another secondary end-point was the comparison of
adenoma versus all without significant findings or with non-
malignant findings. TIMP-1 and CEA were both
significantly associated with the diagnosis of adenoma
[OR=2.3, 95% CI=1.6-3.3, p<0.0001 (AUC=0.597)] as well
as CEA [OR=1.2, 95% CI=1.1-1.3, p=0.004, (AUC=0.554)].
However, adjustment for age led to non-significant results
(TIMP-1: p=0.28; CEA: p=0.26).
Discussion
The present study was designed to validate the hypothesis
that the levels of soluble TIMP-1 and CEA are associated
with presence of CRC. The study was designed as a
prospective study consecutively including individuals
referred for endoscopy for various reasons, including
symptoms which could be attributable to the presence of
CRC, but also individuals with no symptoms. The primary
end-point was CRC. Due to the design of the study, which
is different from that of our previous study (3) in which we
predominantly included symptomatic individuals, the
present study only had 1.6% (95% CI: 1.1-2.3%) patients
with CRC while our previous study had 6.5%. The present
study thus more closely resembles a screening population
where the incidence of CRC is estimated to be
approximately 0.7% (22). The TIMP-1 and CEA
measurements were analysed as in the former study and
sampling done according to the same Standard Operating
Procedure (19). The biomarker levels detected are also
remarkably similar to those reported earlier (3).
Our previous prospective study (3) demonstrated a
significant association between plasma levels of CEA and
TIMP-1 and the presence of CRC. The AUCs for each
biomarker and the multivariable analysis were 0.695 for
TIMP-1, 0.731 for CEA and 0.752 for both combined, and
thus comparable to the results of our previous study (0.71,
0.73 and 0.76, respectively). Of particular interest is that our
very first study which was based on a retrospective analysis
testing the discriminatory potential of TIMP-1 suggested
that the association between plasma TIMP-1 levels and CRC
was strongest for CC (1), and this finding was confirmed in
the first study (3) as the results demonstrated a higher AUC
when restricting the analysis to CC. 
The number of patients with CRC was low due to the
design of the study and accordingly the statistical power
and also the validity of multivariable modelling must be
interpreted with caution. The multivariable modelling for
the primary end-point was therefore only performed for
CEA and TIMP-1 when adjusted for age. 
The results obtained on other the end-point, adenoma,
were also comparable with our previous results. Both
TIMP-1 and CEA levels were able to statistically
discriminate those with adenomas from individuals with
other non-malignant findings and healthy individuals, but
ANTICANCER RESEARCH 35: 4935-4942 (2015)
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Table III. Association of TIMP-1 and CEA with co-morbidity. Examples
of biomarker levels for patients with co-morbidities compared to
individuals without co-morbidity adjusted for age and gender.
Disease group TIMP1 CEA
Elevated by 95% CI Elevated by 95% CI
Cardiovascular disease 19% 12-26% 24% 0-53%
Chronic lung disease 9% 2-17% 24% −6-23%
Diabetes 20% 10-30% −5% −29-27%
Metabolic disease 5% −2-11% −8% −26-15%
CI: Confidence interval.
Figure 1. ROC curves for CEA (blue line), TIMP-1 (red line) and the
combined model for the discrimination of CRC (black line) versus all
other patients included in the study.  
when age was included in the model, the significance
disappeared. Therefore a clinical use of plasma TIMP-1 or
CEA in identifying individuals with adenoma is doubtful.
The occurrence of co-morbidities were registered and
TIMP-1 as well as CEA levels were found elevated for
several of these. For example, for cardiovascular disease,
the plasma TIMP-1 level was 19% higher than in those not
having this co-morbidity. This implies that co-morbidity
should be included when using plasma TIMP-1 or CEA
levels in the assessment of CRC. 
Other blood-based markers have been suggested for the
detection of CRC. Detection of methylated Septin 9 DNA
has been shown to have high sensitivity and specificity
(23). This study was retrospective and the healthy
populations does represent a screening population. Testing
for methylation of Septin 9 DNA in sera from a screening
population (22) would most probably reduce the sensitivity
and specificity of the test. Another potential serological
marker for CRC is the receptor for the urokinase
plasminogen activator (uPAR). Serum levels of uPAR and
its cleaved forms was tested in a case–control study
demonstrating a significant difference in serum levels of
domain I between patients with CRC and patients without
malignant findings or no significamt findings (24).
However, additional studies are required before the
potential value of cleaved forms of uPAR in early detection
of CRC can be finally evaluated.
Another non-invasive method for CRC screening is the
testing of stool for DNA mutations. This test has been used
extensively and has been shown to result in reduced
mortality from CRC in screened individuals (25). It has
been recently been suggested that the stool DNA test is
more accurate than the Septin 9 plasma test in the detection
of CRC (2). There is, the poor compliance rate effectively
reduces the clinical sensitivity of the test. 
A final evaluation of the clinical relevance of the
serological or stool test for CRC detection must be based
on a stringently designed study which includes covariates
that may influence outcome, as well as biomarker levels.
Many of the published studies are based on retrospective
populations, which may not be representative of screening
populations and others are case–control designs. Although
these are useful for initially testing potential biomarker
usefulness, the hypothesis must be tested in prospective
studies. A framework for the development of biomarkers
for clinical use has been outlined (26, 27). The question of
clinical relevance should also be addressed; Does the
screening method provide benefit to the screened
individuals (28).
The strength of our studies are its prospective design
and inclusion of relevant covariates, the latter could be
confounders or mediators. The first study was
representative of the population of interest (19);
individuals were referred to public hospitals for
examination. All of these individuals had symptoms related
to CRC. Individuals in the present cohort were examined
at two private clinics and not necessarily referred due to
symptoms. This may explain the difference in the rate of
CRC detected.
In conclusion, our prior reported findings of an
association between plasma TIMP-1 and CEA levels and
CRC has now been validated in a prospective study
including both symptomatic and non-symptomatic
individuals. The estimated sensitivities and specificities in
the present study, which approximated to our previous
findings, are not considered sufficiently high to warrant the
use of plasma TIMP-1 and CEA as a screening test for
CRC. However, plasma TIMP-1 and CEA are easy to
measure and may provide supplemental information and
thus be combined with other biomarkers (3).
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Table IV. Discrimination using TIMP1 and CEA between the different endoscopy findings. Pairwise comparisons of the findings. The area under the
receiver operating characteristic curve (AUC) for each parameter are shown with the p-value for the Mann–Whitney U-test in parentheses.
AUC (p-value)
Endoscopy findings Parameter Colonic cancer Adenoma Non-malignant
Rectal cancer TIMP1 0.64 (0.28)
CEA 0.64 (0.28)
Adenoma TIMP1 0.68 (0.004)
CEA 0.64 (0.02)
Non-malignant TIMP1 0.73 (0.0001) 0.58 (<0.0001)
CEA 0.67 (0.006) 0.55 (0.025)
No findings TIMP1 0.76 (<0.0001) 0.62 (<0.0001) 0.53 (0.06)
CEA 0.68 (0.004) 0.56 (0.003) 0.51 (0.31)
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